New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
10:28 EDTCNATConatus mentioned positively by The Street's David Sobek
Reference Link
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
16:05 EDTCNATConatus announces acceptance of abstracts for AASLD annual meeting
Conatus Pharmaceuticals announced that abstracts for two posters addressing preclinical results with the company's pan-caspase inhibitors, have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, or AASLD, in San Francisco November 13-17. Accepted abstracts were published today on the AASLD website at for posters entitled, "Alcohol stimulates macrophage activation through caspase dependent, hepatocyte derived release of CD40L containing extracellular vesicles," and "Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of long-term common bile-duct ligation."
September 25, 2015
12:13 EDTCNATConatus management to meet with SunTrust
Subscribe for More Information
September 24, 2015
13:38 EDTCNATConatus mentioned positively at Brean Capital
10:13 EDTCNATHigh option volume stocks
Subscribe for More Information
09:05 EDTCNATOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
06:36 EDTCNATConatus to host conference call
Subscribe for More Information
September 23, 2015
16:33 EDTCNATConatus up 37% after Phase 2 PH trial of emricasan met primary endpoints
Subscribe for More Information
16:08 EDTCNATConatus to resume trading at 4:30 pm ET
Quotes resume at 4:25 pm ET.
16:07 EDTCNATConatus says Phase 2 PH trial of emricasan met primary endpoints
Conatus Pharmaceuticals announced that the company's exploratory Phase 2 Portal Hypertension clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints: a) a clinically meaningful and statistically significant change from baseline in hepatic venous pressure gradient, a measurement of pressure in the portal vein, in patients with liver cirrhosis and severe portal hypertension (HVPG greater than or equal to12 mmHg); and b) a statistically significant change from baseline in cleaved Cytokeratin 18, a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable liver cirrhosis patient population. The open-label PH trial was conducted at nine U.S. sites and enrolled 23 patients with portal hypertension and compensated liver cirrhosis that was predominantly due to nonalcoholic steatohepatitis or hepatitis C virus, including patients with active HCV infection and patients who had a sustained viral response to antiviral therapy. Portal hypertension, or elevated blood pressure in the major vein feeding into the liver, was confirmed by HVPG measurement greater than5 mmHg at baseline and measured again after treatment with 25 mg of emricasan orally twice daily for 28 days. Patients were divided according to the HVPG therapeutic threshold of 12 mmHg, which indicates more severe portal hypertension. Reducing the HVPG to below 12 mmHg or reducing HVPG by greater than or equal to10% or greater than or equal to20% has been strongly associated with clinical benefit in this patient population. The HVPG endpoint was analyzed in: a) patients with baseline HVPG values greater than or equal to12 mmHg (N=12); b) patients with baseline HVPG values less than12 mmHg (N=10); and c) all evaluable patients (N=22). HVPG measurement was standardized, and tracings were evaluated by a single expert reader not otherwise involved in the PH trial. HVPG decreased by a mean of 3.7 mmHg from the mean baseline of 20.6 mmHg in the higher baseline HVPG group (pless than0.003), with 8 of 12 achieving a greater than or equal to10% decrease, 4 of 12 achieving a greater than or equal to20% decrease, and 2 of 12 achieving reductions below 12 mmHg. The changes from baseline HVPG were not statistically significant in the lower baseline HVPG group (+1.9 mmHg mean increase from mean baseline of 8.1 mmHg; p=0.12) or the total evaluable patient population (-1.1 mmHg from mean baseline of 15.2 mmHg; p=0.26). The cCK18 endpoint, analyzed in the total evaluable patient population, showed a statistically significant reduction (pless than0.03) from baseline. Consistent with results from prior trials, emricasan was safe and well tolerated in the PH trial, with no dose-limiting toxicities and no drug-related serious adverse events. Detailed results are expected to be presented in a future scientific forum. As liver cirrhosis progresses, portal pressure increases and hepatic function is eventually lost. Importantly, portal hypertension is largely responsible for events of hepatic decompensation including variceal bleeding, ascites, and encephalopathy, which contribute substantially to morbidity and mortality in these patients. By lowering elevated portal pressures, emricasan has the potential to decrease the risk of hepatic decompensation in liver cirrhosis patients over the short term, and may improve both liver function and structure over the long term through anti-inflammatory and anti-fibrotic effects.
16:05 EDTCNATConatus says Phase 2 PH trial of emricasan met primary endpoints
Subscribe for More Information
16:01 EDTCNATConatus trading halted, news pending
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use